156 related articles for article (PubMed ID: 23900871)
1. Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study.
Białas M; Okoń K; Dyduch G; Ciesielska-Milian K; Buziak M; Hubalewska-Dydejczyk A; Sobrinho-Simoes M
Pol J Pathol; 2013 Jun; 64(2):129-35. PubMed ID: 23900871
[TBL] [Abstract][Full Text] [Related]
2. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
3. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract][Full Text] [Related]
4. S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas.
Unger P; Hoffman K; Pertsemlidis D; Thung S; Wolfe D; Kaneko M
Arch Pathol Lab Med; 1991 May; 115(5):484-7. PubMed ID: 1673596
[TBL] [Abstract][Full Text] [Related]
5. Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodies.
Portela-Gomes GM; Stridsberg M; Grimelius L; Falkmer UG; Falkmer S
APMIS; 2004 Oct; 112(10):663-73. PubMed ID: 15601318
[TBL] [Abstract][Full Text] [Related]
6. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
7. Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas.
Jovanovic R; Kostadinova-Kunovska S; Bogoeva B; Spasevska L; Petrusevska G
Prilozi; 2012; 33(2):23-40. PubMed ID: 23425867
[TBL] [Abstract][Full Text] [Related]
8. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
[TBL] [Abstract][Full Text] [Related]
9. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
[TBL] [Abstract][Full Text] [Related]
10. A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma.
Sangoi AR; McKenney JK
Am J Surg Pathol; 2010 Mar; 34(3):423-32. PubMed ID: 20154585
[TBL] [Abstract][Full Text] [Related]
11. [Distinction between benign and malignant pheochromocytomas].
Liu TH; Chen YJ; Wu SF; Gao J; Jiang WJ; Lu ZH; Guan J; Wei SZ; Luo YF; Cao JL; Wan JW
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):198-202. PubMed ID: 15256107
[TBL] [Abstract][Full Text] [Related]
12. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
[TBL] [Abstract][Full Text] [Related]
13. Criteria for predicting the outcome of pheochromocytoma by the immunohistochemical and electron microscopic findings.
Bezuglova TV
Bull Exp Biol Med; 2003 Oct; 136(4):408-10. PubMed ID: 14714096
[TBL] [Abstract][Full Text] [Related]
14. Pheochromocytoma in Dogs Undergoing Adrenalectomy.
Zini E; Nolli S; Ferri F; Massari F; Gerardi G; Nicoli S; Romanelli G; Montinaro V; Trez D; Cavicchioli L; Ferro S
Vet Pathol; 2019 May; 56(3):358-368. PubMed ID: 30595108
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas.
Nagura S; Katoh R; Kawaoi A; Kobayashi M; Obara T; Omata K
Mod Pathol; 1999 Dec; 12(12):1107-11. PubMed ID: 10619262
[TBL] [Abstract][Full Text] [Related]
16. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases.
Thompson LD
Am J Surg Pathol; 2002 May; 26(5):551-66. PubMed ID: 11979086
[TBL] [Abstract][Full Text] [Related]
17. A comparative immunohistochemical study of spontaneous and chemically induced pheochromocytomas in B6C3F1 mice.
Hill GD; Pace V; Persohn E; Bresser C; Haseman JK; Tischler AS; Nyska A
Endocr Pathol; 2003; 14(1):81-91. PubMed ID: 12746566
[TBL] [Abstract][Full Text] [Related]
18. A review of clinicopathologic features of pheochromocytomas in Hong Kong Chinese.
Lam KY; Chan AC; Wong WM; Lam KS
Eur J Surg Oncol; 1993 Oct; 19(5):421-7. PubMed ID: 8405477
[TBL] [Abstract][Full Text] [Related]
19. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors.
Yon L; Guillemot J; Montero-Hadjadje M; Grumolato L; Leprince J; Lefebvre H; Contesse V; Plouin PF; Vaudry H; Anouar Y
J Clin Endocrinol Metab; 2003 Jun; 88(6):2579-85. PubMed ID: 12788858
[TBL] [Abstract][Full Text] [Related]
20. Pheochromocytomas, PASS, and immunohistochemistry.
Carlsen E; Abdullah Z; Kazmi SM; Kousparos G
Horm Metab Res; 2009 Sep; 41(9):715-9. PubMed ID: 19718615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
